



OUTSOURCING

Emerging Clinical Trial Locations – Eastern Europe

Market dynamics and the changing healthcare and regulatory environment

By Paul Taylor Ph.D. MBA

Paul Taylor

Paul Taylor is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. Dr Taylor has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last ten years Dr Taylor has focused on the structure, organization and functioning of the European healthcare systems with particular focus on reimbursement systems, analyzing specific European product market segments and advising/preparing strategic business and marketing plans for international pharmaceutical, medical devices and healthcare technology companies.

Copyright © 2009 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Emerging clinical trial locations - Eastern Europe

Executive summary	10	
Introduction	10	
Conducting clinical trials in emerging markets	11	
Central and Eastern Europe	12	
Chapter 1	Introduction	14
Summary		14
Introduction		15
Generic competition		15
Intellectual property protection		15
Managing regulatory compliance		17
Cost containment and government funding restrictions		18
Obtaining and maintaining competitive advantage		18
Recruitment and retention of a skilled workforce		19
Improvement to R&D productivity		20
High risks and costs associated with drug development		20
Escalating costs of clinical trials		20
Global increase in the number of clinical trials conducted		23
Longer R&D timelines		24
Increased attrition rates during R&D		26
Clinical trial study design and planning		27
Clinical trial study design		27
Clinical trial study protocol		28
Clinical trial sponsors		28
Identifying and recruiting patients		28
Role of CROs		29
Information technology and new technology platforms		29
Drivers of development		30
Advantages associated with EDC		30
Advantages of electronic Clinical Trial Management Systems (CTMS)		30
Cost saving		31
Issues and challenges		31

Electronic records and signatures	31
Integration and linkage of electronic systems	32
Security and confidentiality of patient data	32

Chapter 2 Conducting clinical trials in emerging markets 36

Summary	36
Introduction	37
Market drivers	39
Rapid recruitment of patients and clinical trial investigators	39
Significant cost benefits	41
Improving transparency and efficiency of regulatory systems	42
Harmonization and standardization of regulatory requirements	43
Expansion of CROs	44
Conducive hospital infrastructure and healthcare systems	46
Enhanced clinical site effectiveness	47
Future commercial value	49
Key barriers	50
Concerns over the clinical trial transparency	50
Publication bias	51
Selective reporting	52
Duplicate publication	53
Conflict of interest	53
Availability of demographic and epidemiology data	53
Critical components concerning capacity building	53
Assimilation of individual national regulations and guidelines	56
United States	56
Japan	57
European Union	58
Language translation	59
Ethical challenges	60
Health needs of the population under study	60
Respect for potential and enrolled subjects	61
Ethical oversight	61
Lack of review by institutional review board (IRB)	61
Absence of informed consent	62
Scientific validity	63
Inadequate protection of intellectual property	64
Clinical trial logistics	64
Import licenses and applications	64
Customs regulations	65
Storage, handling and distribution	66
Selecting an appropriate CRO	67
Patient enrolment	70
Site selection	70
Site activation	71

Patient recruitment	71
---------------------	----

Chapter 3 Central and Eastern Europe 74

Summary	74
Introduction	75
Geographic	75
Czech Republic	76
Poland	76
Russian Federation	76
Political	76
Czech Republic	76
Poland	77
Russian Federation	77
Economic	77
Czech Republic	77
Poland	78
Russian Federation	78
Market dynamics	79
Vital statistics	79
Population statistics	79
Epidemiology and prevalence of major diseases	81
Pharmaceutical market	84
CRO market	86
Czech Republic	86
Poland	86
Russian Federation	87
Clinical trial market	89
Czech Republic	91
Poland	91
Russian Federation	92
Market drivers	95
Large eligible treatment naïve population who exhibit high retention rates	95
Large pool of dedicated, well trained and motivated investigators	95
Cost savings	96
Centralized healthcare systems and well-developed referral systems	97
Entry of Russian Federation into the World Trade Organization (WTO)	97
Positive assessments by the US FDA (Poland)	98
Key barriers	98
Poor hospital infrastructure with inadequate medical equipment	98
Cultural differences and issues	99
Potential delays importing the study drug (Russia)	99
Concerns and issues obtained from regulatory inspections by the FDA (Russia)	100
Lack of clinical trial experience amongst hospital staff and hospital services	102
Healthcare	102
Healthcare system – Czech Republic	102

Hospital resources – Czech Republic	103
Healthcare system – Poland	104
Ministry of Health	104
National health fund	104
Territorial self-government administrations	104
Hospital resources – Poland	105
Healthcare system – Russian Federation	105
Hospital resources – Russian Federation	106
Regulation and legislation	108
Regulatory authorities	108
SUKL – Czech Republic	108
NIL – Poland	109
RZN – Russian Federation	110
Clinical trial regulation	111
Czech Republic	112
Poland	116
Russian Federation	116
Legislation	119
Poland removes tax block for clinical trials	119
Decree no. 226/2008 on good clinical practices - Czech Republic	119
Russia	119
Outlook	120

Chapter 4 Appendix 122

Introduction to clinical trials	122
Clinical trial phases	122
Phase I	122
Phase II	122
Phase III	123
Phase IV	123
What is a clinical trial	123
Clinical trials of pharmaceutical agents	124
Types of clinical trial	125
Pilot studies	125
Proof of concept (PoC) trials	125
Randomized clinical studies	125
Controlled clinical trials	125
Parallel studies	126
Parallel group trials	126
Cohort studies	126
Case control studies	126
Role of the chief investigator	127
Clinical trial protocol and procedure	127
Determination of the clinical trial size	128
Role of the coordinating centre and trials unit	128
Role of the trial coordinator	128
The trial principle investigator	129

Forms and data management	129
Trial data analysis and evaluation	130
Ethical issues and conduct of clinical trial research	130
Interpretation and publication of clinical trial results	131
Principle regulatory agencies	131
The European Agency for the Evaluation of Medicinal Products (EMA)	131
The United States Food and Drug Administration (US FDA)	131
Japanese Ministry of Health, Labor and Welfare (MHLW)	132
Methodology statement	133
Primary Data and Information Gathering	133
Secondary data and information gathering	134
Definitions of Product-Life Cycle stages	136
Glossary of abbreviations and acronyms	137

List of Figures

Figure 1.1:	Key issues facing Pharma and Biotech companies	16
Figure 1.2:	Cost of bringing a drug to market (\$m), 1975-2008	21
Figure 1.3:	Pharmaceutical R&D expenditure (\$bn), 2004-2009e	22
Figure 1.4:	Biotechnology R&D expenditure (\$bn), 2004-2009e	22
Figure 1.5:	Cost of clinical trials in the US (\$bn), 2005-2011e	23
Figure 2.6:	Comparison of locations across selected countries	38
Figure 2.7:	Korean Food and Drug Administration (KFDA) Approval Process	43
Figure 2.8:	CRO Segment Leaders	45
Figure 2.9:	Enhanced clinical site effectiveness (patients per site) in the emerging countries	48
Figure 2.10:	Fewer ineffective sites in the emerging countries	48
Figure 2.11:	Critical components for capacity building/conducting clinical trials	54
Figure 2.12:	Assessing clinical trial location feasibility	55
Figure 2.13:	CRO selection criteria	70
Figure 3.14:	Pharmaceutical market by selected Central and Eastern European countries, 2007	84
Figure 3.15:	Clinical trials Europe	90
Figure 3.16:	Clinical trials by phase (no trials) in the Czech Republic, 2008	91
Figure 3.17:	Clinical trials market (\$m) in Poland, 2007-2010	92
Figure 3.18:	Clinical trials by therapy area (%) in Russia, 2008	93
Figure 3.19:	Clinical trials by phase (%) in Russia, 2008	94
Figure 3.20:	FDA inspection deficiencies in Russian sites	101

List of Tables

Table 2.1:	Demographics of selected emerging markets, 2007	40
Table 2.2:	Ethical principles & their application for research	62
Table 3.3:	Central and Eastern Europe population projection (m people), 2009	79
Table 3.4:	Population statistics - Russia	80

Table 3.5:	Principle city population statistics – Russia, 2008	81
Table 3.6:	Estimated total deaths (thousands) by cause and by selected country	83
Table 3.7:	Top 10 pharmaceutical companies (\$m) in Russia, Poland and the Czech Republic, 2008	85
Table 3.8:	Major CROs operating in Eastern Europe (including Poland and Czech Republic), 2009	87
Table 3.9:	Top 10 Russian regions by no. of new investigative sites, 2006-2008	93
Table 3.10:	Snapshot of hospitals in the Czech Republic	103
Table 3.11:	Snapshot of hospitals in Poland	105
Table 3.12:	Contact details regulatory authorities in selected Central and Eastern European countries	109
Table 3.13:	Fees for clinical trial application (€) in the Czech Republic, April 2009	113
Table 3.14:	Guidelines and Forms for Clinical Trials Czech Republic	114
Table 3.15:	Checklist of documents for initial application in Czech Republic	115